by Heart failure, a major cause of mortality globally, arises when the heart loses its capacity to pump blood efficiently due to the demise of healthy cardiac cells. In the case of heart failure, these cells transform into fibrotic cells, which can no longer contract and relax effectively. This rigidity in cardiac cells hampers their ability to transport blood efficiently to other organs in the body. Unfortunately, humans do not possess the ability to regenerate these cardiac cells, leaving patients with limited options for recovery, primarily preventative or symptomatic treatments.
some mammals are capable of regenerating cardiac cells, albeit for a brief period following birth. Inspired by this natural ability, Mahmoud Salama Ahmed, Ph.D., and an international team of researchers embarked on a mission to discover novel therapeutics or existing therapeutic regimens previously approved by the Food and Drug Administration (FDA) for cardiac regeneration. This research complements the development of Cardiac Rhythm Management Devices, which are essential in treating heart rhythm disorders, highlighting the ongoing advancements in cardiac care.
The team’s study, published in March in Nature Cardiovascular Research, is titled “Identification of FDA-approved drugs that induce heart regeneration in mammals.” This research represents a significant step forward in the quest for effective treatments for heart failure.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
